Classical corticosteroids and new lipid peroxidation inhibitors in the therapy of multiple organ failure (MOF)

Minerva Chirurgica

Volumn 52, Issue 9, 1997, Pages 1095-1102

  Chiara, O ^a,b   Padalino, P ^a   Fattori, L ^a   Ravizzini, C ^a   Turconi, M G ^a   Tiberio, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CD11 ANTIGEN; CD18 ANTIGEN; COMPLEMENT; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LEUKOTRIENE; LIPID PEROXIDATION INHIBITOR; METHYLPREDNISOLONE; PROSTAGLANDIN; STEROID; THROMBOXANE A2; TIRILAZAD; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; COMPLEMENT ACTIVATION; INFLAMMATION; LIPID PEROXIDATION; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PHAGOCYTE; REVIEW; SEPSIS; SEPTIC SHOCK;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CLINICAL TRIALS; FREE RADICAL SCAVENGERS; HUMANS; INJECTIONS, INTRAPERITONEAL; LIPID PEROXIDATION; METHYLPREDNISOLONE; MULTIPLE ORGAN FAILURE; PREGNATRIENES; PROSPECTIVE STUDIES; RABBITS; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; SHOCK, SEPTIC; ZYMOSAN;

EID: 0030726045     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Increase in national hospital discharge survey rates for septicemia. United States 1979-1987, MMWR 39:31-4.
2. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115;457-69.
3. Parrillo JE, Parker MM, Natason C. Septic shock: advances in the understanding of pathogenesis, cardiovascular disfunction and therapy. Ann Intern Med 1990;113:227-42.
4. Michalek SM, Moore RN, McGhee JR et al. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 1980;141:55-63.
5. Wolf SM. Biological effects of bacterial endotoxin in man. J Infect Dis 1973;(Suppl.):259-64.
6. Johnston RB Jr. Monocytes and macrophages. N Engl J Med 1988;318:747-52.
7. Tracey KJ, Vlassara H, Cerami A. Cachectin-tumor necrosis factor. Lancet 1989;1:1122-6.
8. Harris RL, Musher DM, Bloom K et al. Manifestations of sepsis. Arch Intern Med 1987;147:1985-906.
9. Petrak RA, Balk RA, Bone RD, Prostaglandins, cyclooxygenase inhibitors and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure Crit Care Clin 1989;5:303-14.
10. Cotran RS, Pober JS Cytokine endothelial interactions in inflammation, immunity and vascular injury. J Am Soc Nephrol 1990,1:225-35.
11. Frank MM. Complement in the pathophysiology of human disease. N Engl J Med 1987;316:1525-30.
12. Shalaby MR, Aggarwal BB, Rinderknect E et al. Activation of human polymorphonuclear neutrophils functions by interferon-gamma and tumor necrosis factor. J Immunol 1985;135:2069-73.
13. Jacobs RS, Tabor DR. Immune cellular interactions during sepsis and septic injury. Crit Care Clin 1989;5:9-26.
14. Malech HL, Gallin JI. Netrophils in human disease. N Engl J Med 1987;317:687-94
15. Lillehil RD, Longerbeam JK, Blook JH. Physiology and therapy of bacteremic shock. Am J Cardiol 1963;12:599-613.
16. Bone RC, Fischer CJ, Clemmer TP et al. A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-65.
17. Shumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-41.
18. Sprung CL, Carolis PV, Marcial EH et al The effects of high dose corticosteroids in patients with septic shock. N Engl J Med 1984;311:1137-43.
19. Hinshaw LB, Archer LT, Beller-Todd BK et al. Survival of primates in LD 100 septic shock following steroid antibiotic therapy. J Surg Res 1980,28:151-70.
20. Sjolin J. High dose corticosteroids therapy in human septic shock: has the jury reached a correct verdict? Circ Shock 1991;35:139-51.
21. Hall ED, McCall JM, Means ED. Therapeutic potential of the lazaroids (21-aminosteroids) in acute CNS trauma, ischemia and subarachnoid hemorrhage. Advances in Pharmacology. In press, 1994.
22. Braughler JM, Pregenzer JF, Chase RL et al. Novel 21-aminosteroids substituted steroids as potent inhibitors of iron-dependent lipid peroxidatidn. J Biol Chem 1982;262:10438-40.
23. Hall ED, Pazara KE, Braughler JM. 21-aminosteroid lipid peroxidation inhibitor U-74006F protects against cerebral ischemia in gerbils. Stroke 1988; 19:997-1002.
24. Anderson DK, Braughler JM, Hall ED et al. Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. J Neurosurg 1988;69:562-7.
25. Hall ED, Yonkers PA. Attenuation of postischemic cerebral hypoperfusion by the 21-aminosteroid U-74006F. Stroke 1988;19:340-4.
26. Hall ED, Yonkers PA, McCall JM. Attenuation of hemorrhagic shock by the non-glucocorticoid 21-aminosteroid U-74006F. Eur J Pharmacol 1981; 47.299-303.
27. Demling RH, Smith M, Gunter R et al. Endotoxin induced lung injury in unanesthetized sheep: effect of methylprednisolone. Circ Shock 1981;8:351-60.
28. Skubitz KM, Craddock PR, Hammerschmidt DE et al. Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause desegregating of granulocyte aggregates in vitro. J Clin Invest 1981;68:13-20.
29. Hammerschmidt DE, White JC, Craddock PR et al. Corticosteroids inhibit complement induced granulocyte aggregation. J Clin Invest 1979;63.798-603.
30. Nuytinik JKS, Goris RJA, Redl H et al. Post traumatic complications and inflammatory mediators. Arch Surg 1986;121:886-90.
31. Sprung CL, Schultz DR, Marcial E et al. Complement activation in septic shock patients. Crit Care Med 1986,14:525-8.
32. Weiland JE, Davis WB, Holter JF et al. Lung neutrotrophils in the adult respiratory distress syndrome. Ann Rev Respir Dis 1986;133:218-25.
33. Ketai LH, Grum CM c3a and adult respiratory distress syndrome after massive transfusion Crit Care Med 1986;14:1001-3.
34. Hohn DC, Meyers AJ, Gherini ST Production of acute pulmonary injury by leukocytes and activated complement. Surgery 1980;88.48-58
35. Borg T, Gerdin B, Hallgren R et al Complement activation and its relationship to adult respiratory distress syndrome. An experimental study in pigs. Acta Anaesthesiol Scand 1984;28:158-65.
36. Craddock PR, Fehr J, Dalmasso AP et al. Hemodialysis leukopenia. pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977;59:879-88.
37. Fosse E, Mollnes THE, Osterud A et al. Effects of methylprednisolone on complement activation and leukocyte counts during cardiopulmonary bypass. Scand J Thor Cardiovasc Surg 1987;21:255-61.
38. Peters Golden M, Bathon J, Flores R et al. Glucocorticoid inhibition of zymosan-induced arachidonic acid release by rat alveolar macrophages. Am Rev Respir Dis 1984,130:803-9.
39. Peters Golden M, Thebert P. Inhibition by methylprednisolone of zymosan induced leukotriene synthesis in alveolar macrophages Am Rev Respir Dis 1987,135:1020-6
40. Blackwell GJ, Flower RJ, Njikapm FP et al Phospholipase A2 activity of guinca pig isolated perfused lungs: stimulation and inhibition by anti-inflammatory steroids. Br J Pharmacol 1978;62:79-89.
41. Hirata F, Schiffman E, Venkatarubramanian K et al. A Phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA. 1980;77:2533-6.
42. Rothut B, Russo-Marie F, Wood J et al. Further characterization of the glucocorticoid-induced antiphospholipase protein "remocortin" Biochem Biopsy Res Commun 1983;117:878-84.
43. Di Rosa M, Flower RJ, Hirata F et al. Nomenclature announcement: antiphospholipase proteins. Prostaglandins 1984;28:441-2
44. Sibbald WJ, Driedgar AA, Finley RJ et al. High dose corticosteroids in the treatment of pulmonary microvascular injury. Ann NY Acad Sci 1982; 384:496-516
45. Balis JU, Paterson JF, Shelly SA et al. Glucocorticoid and antibiotic effect on hepatic microcirculation and associated host responses in lethal gramnegative bacteremia. Lab Invest 1979;40:55-65.
46. Motsay GJ, Albo A, Jaeger T et al. Effects of methylprednisolone, phenoxybenzamine and epinephrine tolerance in canine endotoxin shock Surgery 1983;70:271-9.
47. Braughler JM, Hall ED. Effects of multi-dose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degration and energy metabolism J Neurosurg 1984;61:290-5.
48. Hall ED Neuroprotective pharmacology of methylprednisolone a review J Neurosurg 1992;76:13-22.
49. Bracken MB, Shepard MJ, Collins WF et al. Methylprednisolone or naloxone treatment after spinal cord injury: 1 year follow-up data J Neurosurg 1992;76:23-31.
50. Young LS. Pathogenesis of septic shock, approaches to management. Ann Intern Med 1980,93:723-34.
51. Lillehei RC, Longerbeam JK, Bloch JH et al. The nature of irreversible shock. Experimental and clinical observation Ann Surg 1964;160 682-710.
52. Simatov R Glucocorticoids inhibit endorphin synthesis by pituitary cells Nature 1979;280:684-6.
53. Mellby JC. Systemic corticosteroid therapy. Pharmacology and endocrinologic considerations. Ann Intern Med 1974;81:505-12.
54. McConn R, Del Guercio LRM Respiratory function of blood in acutely ill patient and the effect of steroids. Ann Surg 1971;174:436-50.
55. Mola L, Miller LD. Efficacy of glucocorticoids in preventing mitochondrial metabolic failure in endotoxemia. Circ Shock 1983;10:371-81.
56. Brigham KL, Bowers, RE, McKeen CR. Methylprednisolone prevention of increased lung vascular permeability following endotoxemia in sheep J Clin Invest 1981;67:1103-10.
57. Sibbald WJ, Anderson RR, Reid B et al. Alveolo-capillary permeability in human septic ARDS. Effect of high dose corticosteroid therapy. Chest 1981;79:133-42.
58. Jerome EH, Bonsignore MR, Albertine KH et al Timing of corticosteroid treatment. Effect on lung lymph dynamics in air embolism lung injury in awake sheep. Am Rev Respir Dis 1990,142:872-9.
59. Chiara O, Giomarelli PP, Borrelli E et al. Inhibition by methylprednisolone of leukocyte-induced pulmonary damage. Crit Care Med 1991;19:260-5.
60. Goris RJA, Boekholtz, WKF, Van Bebber IPT et al. Multiple organ failure and sepsis without bacteria. Arch Surg 1986,121.897-901.
61. Steinberg S, Flynn W, Kelley K et al. Development of a bacteria independent model of the multiple organ failure syndrome. Arch Surg 1989;124:1390-5.
62. Chiara O. Experimental model of non-septic organ failure. In: Castagneto M, Gui D, editors. 1990 Update in trauma surgery. Roma: Coletti Editore, 1990:221-6
63. Hall ED, Yonkers PA. McCall JM et al. Effects of the 21-aminosteroid U-74006F on experimental head injury in mice. J Neurosurg 1988,68:456-61.
64. Goris RJA, Boekhorst TPA, Nuytinck JKS et al. Muitiple Organ Failure. Generalized autodestructive inflammation Arch Surg 1985;120:1109-15.
65. Fry DE, Pearlstein L. Fulton RL et al. Multiple system organ failure. The role of uncontrolled infection. Arch Surg 1980;115 136-40.
66. Rinaldo JE. Mediation of ARDS by leukocytes clinical evidence and implications for therapy. Chest 1986,89:590-3.
67. Sacks T, Moldow CF, Craddock PR et al. Oxygen radicals mediate endothelial cell damage by complement stimulated granulocytes J Clin Invest 1978;61:1161-7.
68. Babior BM Oxidants from phagocytes: agents of defense and destruction. Blood 1984,64.959-66.
69. Ziegler FJ, Fischer CJ, Sprung CL et al. Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized double-blind, placebo controlled trial N Engl J Med 1991;324:429-36
70. Ohllson K, Biork P, Bergenfeldt M et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
71. Engelmann H, Aderka D, Rubinstein M et al. A tumor necrosis factor binding protein purified to homogenity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264:11974-80.
72. Schumer W. Corticosteroids in the treatment of septic shock. Prog Clin Biol Res 1987;236:249-59
73. Members of the American College of Chest Physicians/Society of Critical Care Medicine. Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
74. Carrico CJ, Meakins JL, Marshall JC et al. Multiple organ failure. Panel discussion. Arch Surg 1986; 121:196-208.